Mental Health Clinics in Norway, MI Accepting Medicare
2 Mental Health Clinics found. Showing 1 - 2
 Maraki Llc Social Worker Medicare: Medicare Enrolled Practice Location: 724 Main St, Norway, MI 49870 Phone: 906-221-5059 |
David B. Van Holla, M.d., Pc Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 640 Main St, Norway, MI 49870 Phone: 906-779-7001 Fax: 906-779-7006 |
News Archive
Salivary mucins protect teeth from cariogenic bacterium
Salivary mucins, key components of mucus, actively protect the teeth from the cariogenic bacterium, Streptococcus mutans, according to research published ahead of print in Applied and Environmental Microbiology. The research suggests that bolstering native defenses might be a better way to fight dental caries than relying on exogenous materials, such as sealants and fluoride treatment, says first author Erica Shapiro Frenkel, of Harvard University, Cambridge, MA.
Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis
Trubion Pharmaceuticals, Inc. today announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA.
Immunosuppressive drug mycophenolate mofetil may be effective in controlling inflammatory eye diseases
The immunosuppressive drug mycophenolate mofetil, used to prevent rejection of transplanted hearts, kidneys and livers, may also be effective in controlling inflammatory eye diseases, according to a study by Johns Hopkins' Wilmer Eye Institute.
CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
Senate Appropriations Committee approves spending bill that would expand federal funding for embryonic stem cell research
The Senate Appropriations Committee on Thursday voted 26-3 to approve the fiscal year 2008 Labor-HHS-Education spending bill, which includes a provision that would expand the number of human embryonic stem cell lines eligible for federal funding, CQ HealthBeat reports (CQ HealthBeat, 6/21).
› Verified 6 days ago